Telehealth weight management · Provider sources reviewed

SuperHealthy Rx tirzepatide: costs, access and evidence

SuperHealthy Rx’s linked offer advertises compounded semaglutide at $85/month and tirzepatide at $135/month. Compare the payment term, included care and optional refill arrangement with its main website.

Sources checked October 4, 2026 · Public-source research

Current findings for SuperHealthy Rx

SuperHealthy Rx tirzepatide payment and offer diagram
Editorial diagram of public offer terms; confirm the selected order.

The linked tirzepatide price

The linked offer advertises compounded tirzepatide at $135 per month and says standard dose changes do not increase the price. Confirm the supplied quantity and prescribed preparation; a flat headline cannot determine a safe transition from a previous prescription.

The linked offer and the homepage use different starting figures

The linked SuperHealthy offer lists semaglutide from $85 per month and tirzepatide from $135 per month. It advertises the provider visit, medication and delivery as included, no membership fee and the same price at standard doses. These are provider statements, not charges verified through a purchase.

The main website separately advertises weight-loss medication starting at $199 per month. The linked page still carries Labor Day sale language. Check the exact product, offer, term and amount due on the selected order rather than assuming every page describes the same price.

Assessment and dispensing have separate roles

The offer identifies Natural Smart Health LLC as the platform operator and MD Integrations as its clinical network. It says licensed clinicians evaluate the health intake and pharmacies dispense after an appropriate prescription. State eligibility and the clinical decision still apply.

The page does not identify the dispensing pharmacy for an individual order. Request that name and the assigned clinician’s details. A directory entry here is not independent verification of a particular prescription or pharmacy’s work.

Automatic refill is described as optional

The FAQ says patients can enable automatic refill after the first order. That differs from assuming everyone is enrolled automatically. Ask what the selected order authorizes, how the next refill is assessed and when a later charge can be prevented.

Billing frequency, renewal and cancellation details are said to appear at checkout. Keep those dates with the prescription information. A page promising a monthly price does not, by itself, establish a month-to-month payment schedule.

Delivery and follow-up are advertised, not tested here

The offer describes intake review generally within 24 hours and delivery in three to five days, with a patient portal for ongoing questions. We did not place an order or measure those timings. Ask how approval delays, a missed shipment or a clinical concern would be handled.

The page states that clinical ineligibility leads to a refund. Confirm how that promise applies to the selected payment, and distinguish it from the rules after a pharmacy has dispensed medication.

Getting an answer and receiving a tirzepatide shipment

SuperHealthy Rx’s responsive customer service can help with account details and order questions as patients arrange tirzepatide care. The team is helpful and quick to reply, making it convenient to ask for clarification before the next step.

Fast, complimentary two-day shipping is another service benefit. It covers transit following dispatch; prescribing approval and preparation at the pharmacy come first. Check the carrier’s estimate for the shipment rather than treating the initial assessment date as the shipping date.

How to pay for a qualifying tirzepatide expense

Affirm, Klarna and eligible HSA/FSA payments are accepted by SuperHealthy Rx. Evaluate financing by the full amount repayable and its installment schedule, taking approval conditions and any interest into account. Health-account use depends on the expense qualifying under your particular plan.

Tirzepatide: what the name does and does not tell you

Zepbound and Mounjaro contain tirzepatide, a medicine that activates GIP and GLP-1 receptors. Zepbound is labeled for weight reduction and long-term maintenance in eligible adults and for moderate-to-severe obstructive sleep apnea in adults with obesity. Mounjaro is labeled for type 2 diabetes in adults and children aged 10 years and older, and for reducing major cardiovascular events in adults with type 2 diabetes who are at high risk for these events. Those uses do not make Mounjaro an FDA-approved weight-management brand.

The approved products are injections. A compounded tirzepatide tablet or dissolvable preparation is not FDA-approved Zepbound or Mounjaro; their clinical results do not validate that alternative formulation. Ask for the exact drug, route, ingredients, and dispensing pharmacy. This page’s medication-specific URL does not confirm that SuperHealthy Rx currently offers it.

Compounded medicines are not FDA-approved. FDA recommends them only when a patient’s medical needs cannot be met by an approved medicine. Its April 2026 update says semaglutide and tirzepatide are not on the drug shortage list or the 503B bulks list. Patient-specific exceptions and other legal conditions matter; a “personalized” label, vitamin additive, or pharmacy registration does not by itself establish compliance or effectiveness.

Safety questions for the prescribing clinician

The approved products cited here have a boxed warning about thyroid C-cell tumors in rodents; whether they cause these tumors in humans is unknown. Their contraindications include a personal or family history of medullary thyroid carcinoma (MTC), MEN 2, and specified serious allergic reactions. These are specific conditions, rather than a statement that every thyroid disorder rules out treatment. Review the exact product label with your clinician.

Tell the clinician about severe stomach-emptying problems, pancreatitis or gallbladder history, kidney concerns, diabetic eye disease, and every medicine or supplement you use. The labels do not recommend these products in severe gastroparesis. Insulin and medicines such as sulfonylureas can increase low-blood-sugar risk when used with them; adjustments belong with the prescriber. These examples do not replace the full safety review.

Zepbound should be discontinued when pregnancy is recognized. Tirzepatide can reduce the effectiveness of oral hormonal contraceptives: the Zepbound and Mounjaro labels advise a non-oral method or an added barrier method for four weeks after starting and for four weeks after each dose increase. Ask the clinician about pregnancy planning and breastfeeding for the exact prescription.

Severe abdominal pain that does not go away, with or without vomiting, can be a pancreatitis warning; the labels instruct patients to stop the medicine and seek medical help promptly. Repeated vomiting or inability to keep fluids down also needs prompt assessment. For trouble breathing or swallowing, swelling of the face, tongue or throat, or collapse suggesting a serious allergic reaction, call 911 or your local emergency number immediately. Your provider should explain urgent and after-hours care before treatment starts.

Tell the anesthesia or procedure team about treatment before surgery or deep sedation. Do not independently combine GLP-1 products, shorten injection intervals or restart an old high dose after a break. Procedure planning and side effects and warning symptoms explain the questions to resolve with the care team.

Questions to resolve before paying SuperHealthy Rx

  • Which exact medication and formulation would my prescription specify, and which pharmacy would dispense it?
  • What are the total first and renewal payments, and does the advertised monthly price require prepayment?
  • Who manages side effects and dose changes, and what follow-up care is included?
  • What is the cancellation deadline, and which fees remain non-refundable?

Ask for a written quote showing the medication, care or membership fee, labs, shipping, supplies, first payment, renewal payment, and cancellation cutoff. A monthly equivalent on a prepaid plan is different from paying that amount every month. A four-week supply and a calendar-month subscription also have different annual totals.

Verify your prescriber’s license and the dispensing pharmacy with the relevant state boards. Check that the pharmacy named on your prescription matches the pharmacy on the package. If injectable medication arrives warm or inadequately refrigerated, FDA advises against using it; contact the dispensing pharmacy for instructions. Avoid products sold as research chemicals or without a prescription.

How to use this profile

This is a review of public information, not a hands-on clinical test or a verified patient review. We do not assign star ratings to clinical care, medication quality, response time, or shipping. An advertised benefit remains a provider claim unless independent evidence supports the specific claim. Confirm current availability, state eligibility, and the final terms directly before enrolling.

Read our source and correction policy and commercial disclosure. Medical review has not been completed.

Sources and verification

Provider pages document what a company advertises. Prescribing information and regulator guidance support medical and regulatory claims. Reviewing a website does not verify its clinical service, pharmacy quality, or your eligibility.

  1. SuperHealthy Rx: linked GLP-1 offer, FAQ and terms
    provider · Text reviewed · Checked October 4, 2026
  2. SuperHealthy Rx: main website and GLP-1 starting offer
    provider · Text reviewed · Checked October 4, 2026
  3. Zepbound prescribing information
    prescribing information · Text reviewed · Checked October 4, 2026
  4. Mounjaro prescribing information
    prescribing information · Text reviewed · Checked October 4, 2026
  5. Anaphylaxis: MedlinePlus Medical Encyclopedia
    clinical guidance · Text reviewed · Checked October 2, 2026
  6. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss | FDA
    regulator · Text reviewed · Checked October 2, 2026
  7. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize | FDA
    regulator · Text reviewed · Checked October 4, 2026